TG Therapeutics announced its financial results for the first quarter of 2025, with U.S. net product revenue for BRIUMVI reaching $119.7 million. Total sales for the quarter were $120.86 million, surpassing the consensus estimate of $118.43 million.
Despite reporting a net income of $5.1 million, or $0.03 per diluted share, which was below the consensus estimate of $0.17 per share, the company demonstrated strong top-line growth. This performance led to an upward revision of its full-year 2025 U.S. net product revenue target for BRIUMVI to $560 million, an increase from the previous guidance of $525 million.
The company also raised its full-year 2025 global net revenue target to approximately $575 million and projected U.S. net product revenue for BRIUMVI to be $135 million in the second quarter of 2025. TG Therapeutics continues to invest in simplifying the BRIUMVI treatment regimen, advancing subcutaneous BRIUMVI, and developing azer-cel for progressive MS.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.